Humacyte director granted 80,000 stock options
Humacyte, Inc. director Keith Anthony Jones received a grant of stock options for 80,000 shares of Common Stock.
Rhea-AI Filing Summary
Humacyte, Inc. director Keith Anthony Jones received a grant of stock options for 80,000 shares of Common Stock. The options were awarded at an exercise price of $1.08 per share and are held directly. Following the grant, Jones holds 80,000 stock options.
According to the vesting terms, the first 25% of the option becomes exercisable on June 11, 2027. After that date, 1/48 of the option vests on the 11th of each month through June 11, 2030, with the option expiring on June 11, 2036. This is a compensation-related award rather than an open-market purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 80,000 shares
Grant/Award
1 txn
Insider
Jones Keith Anthony
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (right to buy) | 80,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options (right to buy) — 80,000 contracts (Direct)
Footnotes (1)
- F1. The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.
Key Figures
Options granted: 80,000 options
Exercise price: $1.08 per share
Initial vesting date: June 11, 2027
+2 more
5 metrics
Options granted
80,000 options
Stock Options (right to buy) granted to director
Exercise price
$1.08 per share
Exercise price for options on Humacyte Common Stock
Initial vesting date
June 11, 2027
First 25% of option becomes exercisable
Final vesting date
June 11, 2030
Monthly 1/48 vesting installments end
Expiration date
June 11, 2036
Option expiration for the 80,000-share grant
Key Terms
Stock Options (right to buy), exercise price, vesting, expiration date
4 terms
Stock Options (right to buy) financial
"security_title: Stock Options (right to buy)"
exercise price financial
"conversion_or_exercise_price: 1.0800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-06-11T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Humacyte (HUMA) report for Keith Anthony Jones?
Humacyte reported that director Keith Anthony Jones received a grant of 80,000 stock options. These options give him the right to buy Humacyte Common Stock at a fixed exercise price as part of his compensation package, not through open-market trading.
How many Humacyte (HUMA) stock options were granted to Keith Anthony Jones?
Keith Anthony Jones was granted 80,000 stock options linked to Humacyte Common Stock. All 80,000 options are shown as held following the transaction, reflecting a single compensation-related award documented in the Form 4 insider filing.
What is the exercise price of the Humacyte (HUMA) options granted to Keith Anthony Jones?
The options granted to Keith Anthony Jones have an exercise price of $1.08 per share. This means he can buy Humacyte Common Stock at $1.08 per share once the options vest and before they expire, subject to the stated vesting schedule.
When do Keith Anthony Jones’s Humacyte (HUMA) stock options begin to vest?
The first 25% of Keith Anthony Jones’s stock options become exercisable on June 11, 2027. After that initial vesting date, 1/48 of the total option grant vests monthly on the 11th of each month through June 11, 2030.
What is the vesting schedule for the 80,000 Humacyte (HUMA) stock options granted?
The vesting schedule provides that 25% of the options vest on June 11, 2027. The remaining 75% then vest in equal 1/48 monthly installments on the 11th of each month, continuing until June 11, 2030, when the grant is fully vested.
When do Keith Anthony Jones’s Humacyte (HUMA) stock options expire?
The stock options granted to Keith Anthony Jones expire on June 11, 2036. He must exercise any vested options before that expiration date if he wishes to purchase Humacyte Common Stock at the $1.08 per share exercise price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
